Federal award (DELIVERY ORDER, fiscal year 2022)
Recipient: THE INSTITUTE FOR CANCER RESEARCH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-09-21 to 2024-03-20
Current total value of award: $779932
Description: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM:  PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS  TO TITLE: PREVENTING LUNG CANCER BY TARGETING ACTIVATED STAT3